OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes

OPKO Health (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and obesity.

As quoted in the press release:

“Our confidence in this program is supported by the earlier Phase 2 data and we are enthusiastic to be initiating this study in type 2 diabetics to evaluate the effects of a refined dosing regimen of oxyntomodulin on glucose control and weight loss in preparation for a pivotal Phase 3 program. The dual agonist activity of OPK88003 may provide improved benefits in the treatment of diabetes, resulting in better glucose control and improved long-term cardiovascular outcomes, and we believe it has the potential to offer improved benefits compared with the current once-weekly GLP-1 therapies in a growing diabetes market,” stated Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.

Click here to read the full press release.